Evidence map›Paper›PMID 29196930›Full record

ArticleInternational urology and nephrology2018

Association of ALOX12 gene polymorphism with all-cause and cardiovascular mortality in diabetic nephropathy.

Athanasios K Roumeliotis, Stefanos K Roumeliotis, Stylianos A Panagoutsos, Fotis Tsetsos, Marianthi Georgitsi, Vangelis Manolopoulos, Peristera Paschou, Ploumis S Passadakis

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Novel Cardiovascular Risk Factors in Patients with Diabetic Kidney Disease.International journal of molecular sciences · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Genetic variation inDiabetes & vascular disease research
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Athanasios K RoumeliotisDepartment of Nephrology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Stefanos K RoumeliotisDepartment of Nephrology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Stylianos A PanagoutsosDepartment of Nephrology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece. spanagou@med.duth.gr.
Fotis TsetsosDepartment of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece.
Marianthi GeorgitsiDepartment of Medicine, Aristotle University of Thessaloniki, Thessaloníki, Greece.
Vangelis ManolopoulosLaboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Peristera PaschouDepartment of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece.
Ploumis S PassadakisDepartment of Nephrology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Democritus University of Thrace · GRAristotle University of Thessaloniki · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCardiovascular (CV) events are the first cause of death in patients with chronic renal disease (CKD) and in patients with type 2 diabetes mellitus (DM2). The combination of CKD and DM2 elevates the risk of both cardiovascular disease (CVD) and death in this high-risk population. Besides traditional risk factors, such as dyslipidemia, smoking, obesity, and carotid atherosclerosis, novel factors are under investigation such as genetic polymorphisms. Lipoxygenases (LOXs) and their genes are of critical importance in oxidative stress, inflammation, and atherosclerosis. The aim of the study is to clarify a potential ALOX12 role in CVD presence and progress of diabetic patients in different stages of nephropathy.

methodsWe studied 145 patients with a documented history of DM2 for at least 10 years and diabetic nephropathy (DN), mean age 68 ± 9 years, body mass index 31 ± 5 kg/m

resultsThe GG genotype has been significantly associated with cIMT levels above 0.86 mm and with history of MI. Regarding the presence of an atherosclerotic plaque in either carotid artery, no significant association was found when the genotypes were assessed on their own. After grouping, though, GG genotype revealed a significant association between carotid plaque formation and atheromatosis. Kaplan-Meier analysis revealed that ALOX12 gene GG genotype predicted all-cause mortality, CV mortality, and CV events. Similarly, when AA and AG genotypes were grouped, Kaplan-Meier analysis showed that patients with GG genotype presented an even more significant higher all-cause mortality, CV mortality, and CV events compared with AA and AG genotypes combined. After adjustment for several traditional risk factors, multivariate Cox proportional hazard analysis showed that patients with the GG genotype had a significant higher risk of all-cause mortality, a threefold increase in CV mortality, and a twofold increased risk for CV events compared to patients with the AA or the AG genotype.

conclusionALOX12 rs14309 GG genotype expression was found to be significantly associated with MI, higher cIMT, increased CV events, CV, and overall mortality. This phenomenon could be partially explained by the increased platelet proaggregatory activity of AA products and the control they exert in thrombotic occurrence and plaque formation.

Indexed as

Diabetes Mellitus, Type 2Diabetic NephropathiesAgedArachidonate 12-LipoxygenaseCardiovascular DiseasesCause of DeathComorbidityDisease ProgressionFemaleFollow-Up StudiesGreeceHumansMaleMiddle AgedOdds RatioPatient AcuityALOX12 protein, humanArachidonate 12-LipoxygenaseALOX12 gene polymorphismCardiovascular diseaseCarotid intima-media thicknessDiabetic nephropathy

Identifiers

PMID29196930
OpenAlexW2771972759

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.